 Elanco Animal Health Inc. said Wednesday it has entered an agreement to acquire Kindred Biosciences Inc. for about 440 million, adding three potential dermatology blockbusters to its pipeline. Under the terms of the deal, Elanco will pay 9.l254 a share for each Kindred share owned, equal to a 52 premium based on the 30-day average closing price. 